2023 ´ëÇÑ°¨¿°ÇÐȸ•´ëÇÑÇ×±Õ¿ä¹ýÇÐȸ Ãß°èÇмú´ëȸ(1ÀÏÂ÷) : 2023-11-02
±³À°ÀÏÀÚ : 2023-11-02
±³À°Àå¼Ò : ·Ôµ¥È£ÅÚ¿ùµå(¼¿ïÀá½Ç)
±³À°ÁÖÁ¦ : 2023 ´ëÇÑ°¨¿°ÇÐȸ•´ëÇÑÇ×±Õ¿ä¹ýÇÐȸ Ãß°èÇмú´ëȸ(1ÀÏÂ÷)
ÁÖÃÖ±â°ü : ´ëÇÑ°¨¿°ÇÐȸ
´ã´çÀÚ : ´ëÇÑ°¨¿°ÇÐȸ
¿¬¶ôó : 02-2055-1441
À̸ÞÀÏ : ksinfect@ksid.or.kr
±³À°Á¾·ù : ³»°ú, ¼Ò¾Æû¼Ò³â°ú, °áÇÙ°ú, Áø´Ü°Ë»çÀÇÇаú, º´¸®°ú, ¿¹¹æÀÇÇÐ, ¹Ì»ý¹°ÇÐ, ±â»ýÃæÇÐ
Âü¼®¿¹»óÀÎ : 400¸í
Èñ¸ÁÆòÁ¡ : 6Á¡
Áö¿ª : ¼¿ïƯº°½Ã
±³À°½Ã°£ : 10 ½Ã°£ 30ºÐ
¼¼ºÎ¼ö°·á : 140,000¿ø
ºñ°í »çÀüµî·Ï Àü¹®ÀÇ,±âŸ-(Á¤È¸¿ø)Àü¹®ÀÇ,±âŸ100,000/Àü°øÀÇ60,000/´ëÇлý40,000(ºñȸ¿ø)Àü¹®ÀÇ,±âŸ120,000/Àü°øÀÇ80,000/´ëÇлý50,000ÇöÀåµî·ÏÀü¹®ÀÇ,±âŸ-Àü¹®ÀÇ,±âŸ140,000/Àü°øÀÇ100,000/´ëÇлý70,000
±¸ºÐ ¿ùÀÏ °ÀÇ½Ç ½Ã°£ ±³À°Á¦¸ñ °»ç¸í(¼Ò¼Ó) Çʼö°ú¸ñ
±³À°½Ã°£ 11¿ù 02ÀÏ ±×·£µåº¼·ë 08:00~08:50 Áõ·Ê1 3ÀÏÀü ¹ß»ýÇÑ º¹ÅëÀ¸·Î ³»¿øÇÑ 64¼¼ ³²ÀÚ È¯ÀÚ ±èÈñ¼º(ÃæºÏ´ë)
±³À°½Ã°£ 11¿ù 02ÀÏ ±×·£µåº¼·ë 08:00~08:50 Áõ·Ê2 ÀÎÈÄÅëÀ» ÁÖ¼Ò·Î ³»¿øÇÑ 27¼¼ ¿©ÀÚ Á¤ÀºÁÖ(ÇѸ²´ë)
±³À°½Ã°£ 11¿ù 02ÀÏ ±×·£µåº¼·ë 08:00~08:50 Áõ·Ê3 Ç÷û °Å´ë¼¼Æ÷¹ÙÀÌ·¯½º(CMV) Áõ°¡¸¦ ÁÖ¼Ò·Î ³»¿øÇÑ 59¼¼ ¿©ÀÚ È¯ÀÚ ³ë´öÈñ(°¡Å縯´ë)
±âŸ 11¿ù 02ÀÏ ±×·£µåº¼·ë 08:50~08:55 °³È¸»ç ()
±âŸ 11¿ù 02ÀÏ ±×·£µåº¼·ë 08:55~09:00 Ãà»ç ()
±³À°½Ã°£ 11¿ù 02ÀÏ ±×·£µåº¼·ë 09:00~09:20 Minilecture 1. Antimicrobial resistance/Infection control Á¤µÎ·Ã(¼º±Õ°ü´ë)
±³À°½Ã°£ 11¿ù 02ÀÏ ±×·£µåº¼·ë 09:20~09:40 Minilecture 2. Sepsis/biomarker of infectious diseases ¹Ú´ë¿ø(°í·Á´ë)
±³À°½Ã°£ 11¿ù 02ÀÏ ±×·£µåº¼·ë 09:40~09:52 Effectiveness and Immunogenicity of MMR Vaccine against SARS-CoV-2 among Healthcare Workers ¼®Çý¸®(°í·Á´ë)
±³À°½Ã°£ 11¿ù 02ÀÏ ±×·£µåº¼·ë 09:52~10:04 Clinical Characteristics and Outcome of Post COVID-19 Lung Conditions in patients with lymphoma È«ÇÑÅÍ(°¡Å縯´ë)
±³À°½Ã°£ 11¿ù 02ÀÏ ±×·£µåº¼·ë 10:04~10:16 Ä«¹ÙÆä³Û ³»¼º ´ëÀå±Õ°ú Æó·Å¸·´ë±ÕÀ» °¨¿°½ÃÅ°´Â ¿ë±Õ¼º ¹ÚÅ׸®¿ÀÆÄÁöÀÇ Æ¯¼ººÐ¼® ¹Ú¼º¿ë(±¹¸³º¸°Ç¿¬±¸¿ø)
±³À°½Ã°£ 11¿ù 02ÀÏ ±×·£µåº¼·ë 10:16~10:28 ¼ö¼ú ¿¹¹æÀû Ç×»ýÁ¦ »ç¿ë ÀûÁ¤¼º Æò°¡ µî±Þ¿¡ µû¸¥ Ç×»ýÁ¦ »ç¿ë ÆÐÅÏÀÇ Â÷ÀÌ À±Ãʼ®(ÇѾç´ë)
±³À°½Ã°£ 11¿ù 02ÀÏ ±×·£µåº¼·ë 10:28~10:40 Antifungal susceptibility and phylogenetic analysis of clinical and agricultural Fusarium isolates from Korea ³ë´öÈñ(°¡Å縯´ë)
ÈÞ½Ä 11¿ù 02ÀÏ ±×·£µåº¼·ë 10:40~11:00 Coffee break ()
±³À°½Ã°£ 11¿ù 02ÀÏ ±×·£µåº¼·ë 11:00~11:30 Literature review ¼¼±Õ,Áø±Õ ÃÖÆò±Õ(¼¿ï´ë)
±³À°½Ã°£ 11¿ù 02ÀÏ ±×·£µåº¼·ë 11:30~12:00 Literature review ¹ÙÀÌ·¯½º, ¹é½Å ±èÀ±Á¤(°¡Å縯´ë)
±³À°½Ã°£ 11¿ù 02ÀÏ ±×·£µåº¼·ë 12:00~13:00 Long-term safety of ART : The Undiscovered Country Áø¹ü½Ä(±¹¸³Áß¾ÓÀÇ·á¿ø)
±âŸ 11¿ù 02ÀÏ ±×·£µåº¼·ë 13:00~13:30 ±¹¸³Áß¾Ó°¨¿°º´º´¿ø °Ç¸³ ¹× ¿î¿µ °èȹ ÁÖ¿µ¼ö(±¹¸³Áß¾ÓÀÇ·á¿ø)
Åä·Ð 11¿ù 02ÀÏ ±×·£µåº¼·ë 13:30~14:00 ÆгΠÅäÀÇ(30ºÐ) À̵¿°Ç ¿Ü 4¸í(°¡Å縯´ë)
±³À°½Ã°£ 11¿ù 02ÀÏ ±×·£µåº¼·ë 14:00~14:40 Experience from the RECOVERY trial Leon Peto(University of Oxford, UK)
±³À°½Ã°£ 11¿ù 02ÀÏ ±×·£µåº¼·ë 14:40~15:20 Randomized, Placebo Control Trials in COVID-19: Lessons from ACTT John Beigel(National Institute of Allergy and Infectious Diseases, US)
ÈÞ½Ä 11¿ù 02ÀÏ ±×·£µåº¼·ë 15:20~15:40 Coffee break ()
±³À°½Ã°£ 11¿ù 02ÀÏ ±×·£µåº¼·ë 15:40~15:52 CTX-M-15Çü Extended-spectrum ¥â-lactamase »ý¼º ´ëÀå±ÕÀÇ À¯ÀüÀÚ º¯ÀÌ ¿©ºÎ¿¡ µû¸¥ ¼¼±ÕÇÐÀû Ư¡ ºÐ¼® ±ÇÈñÁ¤(ÇѾç´ë)
±³À°½Ã°£ 11¿ù 02ÀÏ ±×·£µåº¼·ë 15:52~16:04 Association of smoking and sepsis incidence: A Nationwide Population-Based Study ÀÌÀºÈ(¿¬¼¼´ë)
±³À°½Ã°£ 11¿ù 02ÀÏ ±×·£µåº¼·ë 16:04~16:16 Intra-host evolution and neutralizing antibody response in persistent SARS-CoV-2 infection receiving B cell depleting treatment ¾È»ó¹Î(¿¬¼¼´ë)
±³À°½Ã°£ 11¿ù 02ÀÏ ±×·£µåº¼·ë 16:16~16:28 ¾Æ½Ã³×Åä¹ÚÅÍ ¹Ù¿ì¸¶´Ï ±ÕÇ÷Áõ ȯÀÚ¿¡¼ Á¶±â »ç¸Á°ú °ü·ÃµÈ ¹Ì»ý¹°ÇÐÀû Ư¡ ºÐ¼® ÀÌÂù¹Ì(¼¿ï´ë)
±³À°½Ã°£ 11¿ù 02ÀÏ ±×·£µåº¼·ë 16:28~16:40 Obesity paradox does not apply to young adult patients with sepsis: Analysis of MIMIC-IV database. ÀÌ¿ë¼·(¿¬¼¼´ë)
±³À°½Ã°£ 11¿ù 02ÀÏ ±×·£µåº¼·ë 16:40~17:10 New antimicrobials for resistant bacteria ¹èÀαÔ(°æ»ó´ë)
±³À°½Ã°£ 11¿ù 02ÀÏ ±×·£µåº¼·ë 17:10~17:40 New antivirals and monoclonal antibodies for viral infections ±è¼ºÇÑ(¿ï»ê´ë)
±³À°½Ã°£ 11¿ù 02ÀÏ ±×·£µåº¼·ë 17:40~18:10 New antifungal agents in development for invasive fungal diseases ¾ÈÁø¿µ(¿¬¼¼´ë)